Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies

Background Aflibercept, a recombinant fusion protein binding VEGF-A, VEGF-B and placental growth factor, inhibits tumor growth by blocking angiogenesis. The aim of this phase I dose-escalation study was to determine the recommended phase II dose (RP2D) of aflibercept in combination with S-1 in Japan...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Invest New Drugs
Prif Awduron: Doi, Toshihiko, Boku, Narikazu, Onozawa, Yusuke, Takahashi, Keishiro, Kawaguchi, Osamu, Ohtsu, Atsushi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer US 2020
Pynciau:
Phase I Studies
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497698/
https://ncbi.nlm.nih.gov/pubmed/31907738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00888-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg